| Literature DB >> 33281710 |
Merlin M Weeda1, Ilanah J Pruis1, Aimee S R Westerveld1, Iman Brouwer1, Barbara Bellenberg2, Frederik Barkhof1,3, Hugo Vrenken1, Carsten Lukas2, Ruth Schneider2,4, Petra J W Pouwels1.
Abstract
Background: In early multiple sclerosis (MS), thalamus atrophy and decreased integrity of the thalamocortical white matter (WM) tracts have been observed. Objective: To investigate the temporal association between thalamus volume and WM damage in the thalamocortical tract in subjects with early MS.Entities:
Keywords: early MS; fractional anisotropy; longitudinal study; mean diffusivity; multiple sclerosis; thalamocortical tracts; thalamus atrophy; white matter damage
Year: 2020 PMID: 33281710 PMCID: PMC7705066 DOI: 10.3389/fneur.2020.575611
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
Figure 1MRI processing example in a 28 year old female with RRMS. Top panels: T2-FLAIR weighted image with LST LPA lesion segmentation (red). Middle panels: T1-weighted lesion filled image with FreeSurfer segmentation, including left and right thalamus (dark green). Bottom panels: non-diffusion weighted image with the registered left thalamus (green) and the probabilistic connectivity distribution map of the corresponding thalamocortical tracts (red-yellow).
Baseline demographics.
| Age in years, mean ± SD | 37.4 ± 10.9 | 37.5 ± 9.4 | 37.4 ± 12.0 | |
| Sex, m/f (%f) | 28/44 (61%) | 13/17 (57%) | 15/27 (64%) | |
| Disease duration in months mean ± SD (range) | 10.7 ± 8.9 (0.8–31.1) | 4.2 ± 3.7 (0.8–4.0) | 15.2 ± 8.7 (1.1–31.1) | |
| Treatment, | ||||
| None | 17 (24%) | 9 (30%) | 8 (19%) | |
| Interferon | 34 (47%) | 15 (50%) | 19 (45%) | |
| Glatiramer acetate | 15 (21%) | 4 (13%) | 11 (26%) | |
| Dimethyl fumarate | 5 (7%) | 2 (7%) | 3 (7%) | |
| Teriflunomide | 1 (1%) | 0 (0%) | 1 (2%) | |
| Treatment duration in months mean ± SD (range) | 4.1 ± 6.9 (0.0–27.3) | 1.2 ± 3.1 (0.0–13.1) | 6.2 ± 8.1 (0.0–27.3) | |
| EDSS, median with IQR | 1.5 (1.5–2.5) | 1.5 (1.5–2.5) | 1.5 (1.0–2.5) | |
| Follow-up time in months mean ± SD (range) | 13.7 ± 4.8 (5.1–27.3) | 12.5 ± 3.1 (7.9–25.4) | 14.5 ± 5.7 (5.1–27.3) |
SD, standard deviation; IQR, interquartile range.
Differences between CIS and RRMS tested by:
Mann–Whitney U-test,
Chi Square test. p-values < 0.05 are highlighted in bold type.
Baseline and follow-up brain volumes and the FA and MD of the tracts connected to the thalamus, shown as mean with standard deviation, as well as the annual percentage change observed.
| Whole brain volume | 1140.3 ± 126.7 | 1131.5 ± 124.6 | −0.65 (−1.52 – −0.01) | |
| WM volume | 446.5 ± 58.6 | 441.7 ± 58.1 | −0.83 (−2.42 – +0.44) | |
| GM volume | 637.4 ± 68.6 | 631.9 ± 67.4 | −0.93 (−2.03 – +0.44) | |
| Thalamus volume | ||||
| Left | 7.15 ± 0.91 | 7.06 ± 0.91 | −1.34 (−2.14 – +0.43) | |
| Right | 6.88 ± 0.84 | 6.78 ± 0.83 | −0.88 (−2.34 – +0.14) | |
| Lesion volume | 12.26 ± 10.10 | 11.73 ± 10.44 | −8.52 (−27.65 – +8.87) | |
| FA | ||||
| Left | 0.545 ± 0.027 | 0.546 ± 0.030 | +0.30 (−1.60 – +1.88) | |
| Right | 0.560 ± 0.030 | 0.558 ± 0.030 | −0.23 (−2.93 – +2.33) | |
| MD | ||||
| Left | 63.98 ± 3.63 | 64.39 ± 4.08 | +0.22 (−1.83 – +3.06) | |
| Right | 62.32 ± 3.90 | 62.91 ± 4.14 | +0.61 (−2.58 – +3.71) | |
Volumes are in ml; MD is in 10.
Figure 2Relation between baseline FA (top row) or baseline MD (depicted as 10−5 mm2/s; bottom row) of the thalamocortical tracts and the annual percentage change in thalamus volume (left and right). Lower baseline FA (B=0.240, p = 0.042) was predictive of more negative annual percentage change of thalamus volume (i.e., atrophy), and a trend was seen for higher baseline MD (B=-0.229, p = 0.053, not significant) with increasing thalamus atrophy, but only in the left thalamus.